These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18803555)

  • 41. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
    Balkrishnan R; Nelsen LM; Kulkarni AS; Pleasants RA; Whitmire JT; Schechter MS
    J Asthma; 2005 Feb; 42(1):35-40. PubMed ID: 15801326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination therapy in asthma--fixed or variable dosing in different patients?
    Lötvall J
    Curr Med Res Opin; 2004 Nov; 20(11):1711-27. PubMed ID: 15537472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
    Markham A; Adkins JC
    Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDA panel: ban 2 popular asthma drugs.
    Kuehn BM
    JAMA; 2009 Jan; 301(4):365-6. PubMed ID: 19176431
    [No Abstract]   [Full Text] [Related]  

  • 45. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ
    Sao Paulo Med J; 2010; 128(5):310-1. PubMed ID: 21181075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
    Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H
    Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma.
    Ställberg B; Ekström T; Neij F; Olsson P; Skoogh BE; Wennergren G; Löfdahl CG;
    Respir Med; 2008 Oct; 102(10):1360-70. PubMed ID: 18723335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
    O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
    Dahl R; Chuchalin A; Gor D; Yoxall S; Sharma R
    Respir Med; 2006 Jul; 100(7):1152-62. PubMed ID: 16675212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.
    Bodzenta-Lukaszyk A; Dymek A; McAulay K; Mansikka H
    BMC Pulm Med; 2011 May; 11():28. PubMed ID: 21605396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
    Vogelmeier C; D'Urzo A; Pauwels R; Merino JM; Jaspal M; Boutet S; Naya I; Price D
    Eur Respir J; 2005 Nov; 26(5):819-28. PubMed ID: 16264042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
    Akamatsu T; Shirai T; Kato M; Yasui H; Hashimoto D; Fujisawa T; Tsuchiya T; Inui N; Suda T; Chida K
    Pulm Pharmacol Ther; 2014 Feb; 27(1):52-6. PubMed ID: 23583566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS).
    Janson C; Larsson K; Lisspers KH; Ställberg B; Stratelis G; Goike H; Jörgensen L; Johansson G
    BMJ; 2013 May; 346():f3306. PubMed ID: 23719639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-inhaler combination therapy for maintenance and relief of asthma: a new strategy in disease management.
    Peters M
    Drugs; 2009; 69(2):137-50. PubMed ID: 19228072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Karner C; Cates CJ; Evans DJ
    Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD007033. PubMed ID: 22161409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK.
    FitzGerald JM; Arnetorp S; Smare C; Gibson D; Coulton K; Hounsell K; Golam S; Sadatsafavi M
    Respir Med; 2020 Sep; 171():106079. PubMed ID: 32917353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.